• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Liminal Biosciences Announces Completion of the Plan of Arrangement With Structured Alpha LP

Share:

October 3, 2023

Liminal BioSciences Inc. has completed its statutory plan of arrangement with Structured Alpha LP (SALP), a limited partnership managed by Thomvest Asset Management Ltd. SALP has acquired all issued and outstanding common shares of Liminal BioSciences, not already owned by SALP or its affiliates, at a price of US$8.50 per share in cash. Shareholders must follow specific instructions to receive their entitlements. Following the arrangement, Liminal BioSciences will delist from the Nasdaq Capital Market and cease to be a reporting issuer under Canadian and U.S. securities laws.

Liminal BioSciences Inc. (“Liminal BioSciences” or the “Company”) is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP (“SALP”), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., was completed earlier today (the “Arrangement”). Pursuant to the Arrangement, SALP acquired all of the issued and outstanding common shares of Liminal BioSciences (the “Shares”) not currently owned by SALP or its affiliates and associates (the “Minority Shares”) at a price of US$8.50 per Share, payable in cash (the “Consideration”).

Registered holders of Minority Shares (“Minority Shareholders”) are reminded that in order to receive any Consideration that they are entitled to, they must properly complete, sign and return the letter of transmittal to Computershare Investor Services Inc., as depositary, together with the share certificate(s) and/or Direct Registration System (DRS) Advice(s) representing Shares formerly held by them. Minority Shareholders who hold their Shares through a broker, investment dealer or other intermediary should carefully follow the instructions provided by such broker, investment dealer or other intermediary.

As a result of the Arrangement, the Shares will no longer be listed on the Nasdaq Capital Market. In addition, the Company will submit an application to cease to be a reporting issuer under applicable Canadian securities law, will file a certification and notice on Form 15 with the U.S. Securities and Exchange Commission to suspend its reporting obligations under U.S. securities laws and will otherwise terminate the Company’s public reporting requirements.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: BioSpace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Tesis Biosciences Acquires Genome Explorations to Accelerate Clinical Research and Product Development for Chronic Disease CuresTesis Biosciences Acquires Genome Explorations to Accelerate Clinical Research and Product Development for Chronic Disease Cures
  • Accenture Acquires UK Digital Health Firm NautilusAccenture Acquires UK Digital Health Firm Nautilus
  • Google Reveals LLM That Helps Accurately Diagnosis Complex CasesGoogle Reveals LLM That Helps Accurately Diagnosis Complex Cases
  • AI Revolution in Drug Discovery AcceleratesAI Revolution in Drug Discovery Accelerates
  • Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled DeliveryProtalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
  • Partnership expanded to support early stage digital health companiesPartnership expanded to support early stage digital health companies
  • US Health Care Companies Begin Exploring Blockchain TechnologiesUS Health Care Companies Begin Exploring Blockchain Technologies
  • SynsorMed, Charles Barkley Foundation Partner to Combat Health Disparities for Black Americans Impacted by COVID-19SynsorMed, Charles Barkley Foundation Partner to Combat Health Disparities for Black Americans Impacted by COVID-19

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications